HYBIO(SZ:300199) Zheng Quan Ri Bao Wang·2025-10-30 05:14Core Insights - The company reported significant growth in its financial performance for the first three quarters of 2025, with revenue reaching 683 million yuan, a year-on-year increase of 82.06%, and a net profit of 71.35 million yuan, marking a turnaround from losses [1] - The operational cash flow reached a historical high of 271 million yuan, reflecting a year-on-year growth of 207.37%, driven by the successful market penetration of its core product, liraglutide injection [1] Financial Performance - Revenue for the first three quarters was 683 million yuan, up 82.06% year-on-year [1] - Net profit attributable to shareholders was 71.35 million yuan, indicating a return to profitability [1] - Operating cash flow was 271 million yuan, representing a 207.37% increase year-on-year, the highest in the same period historically [1] Technological Innovation - The company launched a "Peptide AI Process Optimization Assistant" in collaboration with Huawei Cloud, utilizing over 100,000 historical process data points and global chemical databases to enhance drug development efficiency [2] - The AI assistant has reportedly reduced research and development cycles by 45% and lowered trial and error costs by over 20% [2] - The company is also advancing in new peptide sustained-release technologies, improving drug delivery convenience and optimizing drug action duration [2] CRDMO Business Expansion - The company has been active in the CRDMO (Contract Research, Development, and Manufacturing Organization) sector, forming strategic partnerships to enhance its business ecosystem [3] - Collaborations with Carbon Cloud Peptide focus on innovative peptide drug development, covering the entire process from preclinical research to commercialization [3] - The partnership with Borui Pharmaceutical aims to provide international standard raw material supply for oral peptide products, supporting global industrialization of innovative drugs [3] Capital Increase and Capacity Expansion - The company announced a plan to raise up to 968 million yuan through a private placement to enhance its core peptide drug business [4] - Of the raised funds, 495 million yuan will be allocated to expanding peptide drug production lines and green intelligent upgrades to ensure continuous supply of raw materials [4] - The plan also includes investing 40 million yuan in expanding peptide fragment production, aiming for vertical integration in the pharmaceutical supply chain [4]